ADVANCED SOLID TUMOR

This early-phase study tests a new drug called ISM5939 in people with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors. About 159 participants will receive the drug alo…

This study tests an experimental mRNA treatment injected directly into tumors. It aims to help the body's immune cells attack and kill cancer cells. The trial includes about 60 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to…

This study tests a new tablet, ZL-85FA, in people with advanced solid tumors like breast, ovarian, or prostate cancer. The goal is to see if the drug is safe and can shrink tumors. About 51 adults will take the pill, and doctors will monitor their response and side effects.

This early study tests a new treatment called CAT-101, made from a patient's own immune cells (dendritic cells) loaded with a piece of the cancer-driving KRAS protein. It is given alone or with an immunotherapy drug (tislelizumab) to people with advanced pancreatic cancer or othe…

This early-phase study tests a new drug called ONC-783 in people with advanced solid tumors, including colorectal, ovarian, pancreatic, and breast cancers. The main goal is to find the safest dose and understand how the drug works in the body. About 20 participants will receive t…

This study tests a new drug (IPG7236) combined with an immunotherapy (toripalimab) in adults with advanced solid tumors that have spread or cannot be removed. The goal is to see if the combination is safe and can shrink tumors. About 52 people will take part. This is not a cure—p…

This study tests a new drug called CVL006 combined with standard chemotherapy or other targeted drugs in people with advanced solid tumors that have not responded to prior treatments. The goal is to find the safest dose and see if the combination can shrink tumors or slow their g…

This study tests a new drug called IDP-001 in people with advanced or spreading solid tumors, including certain lung, head and neck, and other cancers. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. About 132 adults who have t…

This early-stage study tests a new drug called JH021 in 60 people with advanced solid tumors that have stopped responding to standard treatments. JH021 is a special antibody designed to attack two cancer-related targets at once. The main goals are to check the drug's safety, find…

This study tests two experimental drugs, TQB2930 and TQB2102, given together to people with advanced solid tumors that have a protein called HER2. The goal is to find the safest and most effective dose and see if the combination can shrink or control the tumors. About 178 adults …

This study tests an experimental drug called BSI-082 in people with advanced or metastatic solid tumors that have stopped responding to standard treatments. In the first part, participants receive BSI-082 alone at increasing doses. In the second part, they receive BSI-082 combine…

This study tracks the safety and effectiveness of envafolimab, a cancer drug given as a quick shot under the skin, in 120 adults with advanced solid tumors. It aims to see how well the drug controls tumors and extends life in everyday medical practice, not just in controlled tria…

This early-phase study tests a new drug called MG2512 in about 116 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see how the body processes it. This is a first step to see i…

This is the first human study of an experimental oral drug called ACC-1898 for adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and understand how the body processes the drug. Participants will take dail…